MA54452A - Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a - Google Patents

Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a

Info

Publication number
MA54452A
MA54452A MA054452A MA54452A MA54452A MA 54452 A MA54452 A MA 54452A MA 054452 A MA054452 A MA 054452A MA 54452 A MA54452 A MA 54452A MA 54452 A MA54452 A MA 54452A
Authority
MA
Morocco
Prior art keywords
inhibitors
derivatives used
methionine adenosyltransferase
oxoquinazoline derivatives
oxoquinazoline
Prior art date
Application number
MA054452A
Other languages
English (en)
Inventor
Muzaffar Alam
Leah Cleary
Melissa Fleury
John E Knox
Zachary E R Newby
Zhonghua Pei
Richard Steel
James Sutton
Original Assignee
Ideaya Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ideaya Biosciences Inc filed Critical Ideaya Biosciences Inc
Publication of MA54452A publication Critical patent/MA54452A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054452A 2018-12-10 2019-12-09 Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a MA54452A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777715P 2018-12-10 2018-12-10
US201962835853P 2019-04-18 2019-04-18
US201962883945P 2019-08-07 2019-08-07

Publications (1)

Publication Number Publication Date
MA54452A true MA54452A (fr) 2022-03-16

Family

ID=69138003

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054452A MA54452A (fr) 2018-12-10 2019-12-09 Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a

Country Status (17)

Country Link
US (4) US20220106276A1 (fr)
EP (1) EP3894396A1 (fr)
JP (1) JP2022512156A (fr)
KR (1) KR20210103498A (fr)
CN (1) CN113166078A (fr)
AU (1) AU2019395338A1 (fr)
BR (1) BR112021010842A2 (fr)
CA (1) CA3121236A1 (fr)
CL (1) CL2021001508A1 (fr)
CO (1) CO2021008895A2 (fr)
IL (1) IL283743A (fr)
MA (1) MA54452A (fr)
MX (1) MX2021006841A (fr)
PH (1) PH12021551274A1 (fr)
SG (1) SG11202105469YA (fr)
TW (1) TW202039487A (fr)
WO (1) WO2020123395A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021252678A1 (fr) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. Dérivés de 2-oxoquinazoline substitués par un alkylène hétéroaryle utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
PE20230685A1 (es) * 2020-06-22 2023-04-21 Hoffmann La Roche Derivados de amidopirimidona
CR20220644A (es) * 2020-06-22 2023-02-17 Hoffmann La Roche Derivados de sulfona
WO2021254529A1 (fr) * 2020-07-14 2021-12-23 江苏先声药业有限公司 Composé bicyclique
WO2022063128A1 (fr) * 2020-09-24 2022-03-31 上海凌达生物医药有限公司 Composé de pyridone cyclique ou arylhétérocyclique aromatique, compositions pharmaceutiques et leur utilisation
AU2021401232A1 (en) * 2020-12-15 2023-06-22 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
WO2022143864A1 (fr) 2020-12-31 2022-07-07 江苏先声药业有限公司 Composé tricyclique et son utilisation
WO2022206730A1 (fr) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 Composé de pyrimidopyrazine et son utilisation
WO2022222911A1 (fr) * 2021-04-19 2022-10-27 武汉人福创新药物研发中心有限公司 Composé pyrimidone et son utilisation
US20240228491A1 (en) * 2021-04-30 2024-07-11 Scinnohub Pharmaceutical Co., Ltd. Methionine adenosyltransferase inhibitor, preparation method therefor and application thereof
CN117412967A (zh) * 2021-06-02 2024-01-16 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
AU2022287057A1 (en) * 2021-06-02 2023-12-14 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
WO2022256808A1 (fr) * 2021-06-02 2022-12-08 Ideaya Biosciences Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de prmt de type i
MX2024003647A (es) 2021-09-24 2024-05-29 Xenon Pharmaceuticals Inc Derivados de piridina y su uso como activadores del canal de sodio.
WO2023066283A1 (fr) * 2021-10-20 2023-04-27 Insilico Medicine Ip Limited Inhibiteurs de la méthionine adénosyltransférase 2a (mat2a) et leurs utilisations
WO2023083210A1 (fr) * 2021-11-09 2023-05-19 上海海雁医药科技有限公司 Dérivé de naphtyridinone substitué, composition pharmaceutique de celui-ci et utilisation de celui-ci
WO2023086934A1 (fr) * 2021-11-12 2023-05-19 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un taxane
AU2022423231A1 (en) 2021-12-21 2024-07-11 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Methionine adenosyltransferase 2a heterocyclic inhibitor
CN118541371A (zh) * 2022-01-26 2024-08-23 勤浩医药（苏州）有限公司 用于治疗mtap缺失型癌症的甲硫氨酸腺苷转移酶2a抑制剂
WO2023177894A1 (fr) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un agent antimétabolite
GB202204913D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd antiviral therapy
WO2023201338A1 (fr) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de parp
KR20240051860A (ko) 2022-10-13 2024-04-22 한미약품 주식회사 신규한 트리사이클 유도체 화합물 및 이의 용도
WO2024118897A1 (fr) 2022-11-30 2024-06-06 Amgen Inc. Traitements du cancer utilisant un inhibiteur de prmt5 et un inhibiteur de mat2a
WO2024118070A1 (fr) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Formes cristallines de 2-oxoquinazoline
WO2024118943A2 (fr) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de prmt5
WO2024118830A1 (fr) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Atropisomères d'inhibiteurs de mat2a
CN116425751B (zh) * 2022-12-19 2024-01-23 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物
CN116283800B (zh) * 2023-05-16 2023-07-18 英矽智能科技(上海)有限公司 氧代喹唑啉类化合物及其应用
CN116478172B (zh) * 2023-06-20 2023-09-05 英矽智能科技(上海)有限公司 吡咯并[3,2-d]嘧啶类化合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5761758B2 (fr) 1974-01-11 1982-12-25 Hisamitsu Pharmaceutical Co
US5874519A (en) 1994-05-11 1999-02-23 Asahi Kasei Kogyo Kabushiki Kaisha Para-oriented aromatic polyamide shaped articles and preparation thereof
US5525711A (en) * 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
EP2266984A1 (fr) 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Pyrido[2,3-d]pyrimidines en tant qu' antagoniste du Wnt pour le traitement du cancer et de l'arthrite
WO2012030160A2 (fr) * 2010-08-31 2012-03-08 Hanmi Holdings Co., Ltd. Dérivés de quinoline ou de quinazoline ayant une activité induisant l'apoptose sur les cellules
US20140227321A1 (en) 2011-09-30 2014-08-14 Kineta, Inc. Anti-viral compounds
US8815877B2 (en) * 2011-12-22 2014-08-26 Genentech, Inc. Serine/threonine kinase inhibitors
EP3383375A1 (fr) * 2015-12-03 2018-10-10 Agios Pharmaceuticals, Inc. Inhibiteurs de mat2a pour le traitement du cancer n'exprimant pas mtap
EP3507290A1 (fr) * 2016-08-31 2019-07-10 Agios Pharmaceuticals, Inc. Inhibiteurs de processus métaboliques cellulaires
RS62456B1 (sr) * 2016-12-22 2021-11-30 Amgen Inc Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
WO2018221433A1 (fr) 2017-05-29 2018-12-06 第一三共株式会社 Dérivé d'amine hétéroaryle
CA3075046A1 (fr) * 2017-09-08 2019-03-14 Amgen Inc. Inhibiteurs de kras g12c et leurs procedes d'utilisation
MA52232A (fr) 2018-03-30 2021-02-17 Agios Pharmaceuticals Inc Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA52501A (fr) * 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
WO2020050890A2 (fr) * 2018-06-12 2020-03-12 Amgen Inc. Inhibiteurs de kras g12c et leurs procédés d'utilisation
US11376256B2 (en) 2018-07-19 2022-07-05 Agency For Science, Technology And Research Method of treating a methionine-dependent cancer
KR20210097715A (ko) * 2018-11-29 2021-08-09 아락세스 파마 엘엘씨 암 치료용 화합물 및 이의 사용 방법
EP3902804A1 (fr) 2018-12-27 2021-11-03 Les Laboratoires Servier SAS Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
PL3902803T3 (pl) 2018-12-27 2023-05-22 Les Laboratoires Servier Aza-heterobicykliczne inhibitory mat2a i sposoby zastosowania do leczenia nowotworu

Also Published As

Publication number Publication date
US20220106276A1 (en) 2022-04-07
MX2021006841A (es) 2021-07-02
TW202039487A (zh) 2020-11-01
PH12021551274A1 (en) 2021-12-06
CO2021008895A2 (es) 2021-07-30
BR112021010842A2 (pt) 2021-08-24
SG11202105469YA (en) 2021-06-29
CN113166078A (zh) 2021-07-23
US11130759B1 (en) 2021-09-28
US11046691B1 (en) 2021-06-29
WO2020123395A1 (fr) 2020-06-18
JP2022512156A (ja) 2022-02-02
KR20210103498A (ko) 2021-08-23
US11084798B1 (en) 2021-08-10
AU2019395338A1 (en) 2021-07-29
CA3121236A1 (fr) 2020-06-18
IL283743A (en) 2021-07-29
CL2021001508A1 (es) 2022-01-21
EP3894396A1 (fr) 2021-10-20

Similar Documents

Publication Publication Date Title
MA54452A (fr) Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a
MA51610A (fr) Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA49013A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA54157A (fr) Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1)
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA51431A (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA44502A (fr) Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA52940A (fr) Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
MA42810A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue